Darlene Dobkowski, MA

Testicular cancer survivors who were treated with cisplatin-based chemotherapy may have hearing loss or ringing of the ears, which may significantly affect certain parts of life including sleep and concentration, among other factors.

The risk for psychiatric disorders increased for spouses of patients with cancer compared with those whose partners did not have cancer.

One patient describes the management of symptoms of graft-versus-host disease as playing Whac-a-Mole and emphasizes the importance of awareness and education for both patients and their families.

From prostate cancer to disease spread in the brain, one patient learned how to recognize how far he has come since his journey began.

One expert explains how the road to cancer drug development isn’t a smooth one, but progress can be made nonetheless.

FDA-approved immunotherapies offer patients with metastatic or recurrent sarcomatoid RCC more treatment choices and improved outcomes.

Patients with relapsed/refractory follicular lymphoma — a group that traditionally has limited treatment options — now have a new bispecific antibody available.

A childhood cancer survivor now works raising funds for Children’s Hospital of Philadelphia, the same hospital where she received treatment for Ewing sarcoma at 12 years old.

The indication for Pemfexy has been approved to include patients with metastatic, non-squamous, non-small cell lung cancer without EGFR or ALK genomic tumor mutations.

Adults with graft-versus-host disease who were treated with a three-drug regimen with cyclophosphamide after transplant may have improved survival rate compared with those treated with a two-drug regimen.

Adstiladrin represents the first gene therapy approved by the FDA for the treatment of patients with high-risk non-muscle invasive bladder cancer who are resistant to BCG, the first-line standard of care for these patients.

Women with multiple ipsilateral breast cancer may have similar recurrence-free outcomes with a lumpectomy as one might encounter with a mastectomy, opening the door for more surgical treatment options for these patients.

Men with obesity before starting prostate cancer treatment may have an increased risk for death from heart disease or any cause rather than from prostate cancer itself, study results showed.

The treatment and support that children with cancer receive has advanced over the past 20 years, but more progress to improve the cure rate is on the horizon.

Tecentriq was approved by the FDA for adults and children aged two years and older with advanced alveolar soft part sarcoma, a disease typically diagnosed in approximately 80 patients per year in the U.S.

Watch Dr. Douglas A. Tremblay, from Mount Sinai, discuss treatment for essential thrombocythemia during the CURE Educated Patient MPN Summit.

Study findings showed that anxiety and depression may not decrease over time in patients with testicular cancer, emphasizing the importance of discussing symptoms with cancer teams.

Actress Kirstie Alley, who is known for roles in “Cheers,” “Look Who’s Talking’” and other television shows and movies, died a short time after receiving a colon cancer diagnosis, according to a family statement.

A nurse shares what it was like when her daughter was diagnosed with an aggressive cancer during the beginning of the COVID-19 pandemic.

A recently conducted study found that for some patients, chemotherapy-induced hiccups were worse than nausea and vomiting.

Watch Dr. Beverly Moy, from Massachusetts General Hospital, discuss addressing breast cancer disparity during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Dejan Juric, from Massachusetts General Hospital, discuss therapeutic resistance during the CURE Educated Patient Metastatic Breast Cancer Summit.

One expert said that the FDA approval of the antibody-drug conjugate Elahere represents a new treatment option for patients with folate receptor alpha-positive, platinum resistant ovarian cancer.

Identifying genetic mutations in lung cancer has allowed researchers to develop treatments that target specific biomarkers over the past 20 years, but more research is needed to further the space.

Patients should describe their symptoms in detail and seek early care for suspected lung cancer, especially since the disease may resemble pneumonia and bronchitis on imaging tests.

Imjudo, Imfinzi and chemotherapy improved overall and progression-free survival in certain patients with non-small cell lung cancer.

Stem cell transplants may cause dysgeusia — a disorder that alters a person’s taste —in some patients with multiple myeloma, which is a type of blood cancer. This disorder may have a domino effect on quality of life, although levels may return to normal a few months after the procedure, an expert said.

Compared with tissue biopsies, liquid biopsies performed with blood samples may inform cancer teams of a patient’s increased risk for blood cancers, although all patients may not have this risk.

Advocacy groups helped one patient with ocular melanoma — and many others — learn more about their disease and treatment, as well as a place to connect about their experiences.

The dual immunotherapy regimen of Imjudo and Imfinzi may provide patients with unresectable hepatocellular carcinoma a well-tolerated treatment to extend survival.